Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review

Table 1 Meta-analyses included for induction of clinical remission in Crohn’s disease

Study	Intervention	Comparator	Follow-up	n	Induction of clinical remission, RR (95%CI)	Quality of evidence
Chande et al[23]	AZA or 6-MP	Placebo	6 wk-9 mo	380	RR 1.23 (0.97-1.55)1	Moderate
	AZA or 6-MP	MTX	6 wk-9 mo	143	RR 1.13 (0.85-1.49)1	Low
	AZA or 6-MP	5-ASA	6 wk-9 mo	156	RR 1.24 (0.80-1.91)1	Very low
	AZA	IFX	26 wk	399	RR 0.66 (0.51-0.87)1	Moderate

¹Clinical remission as measured by individual study with a validated outcome (e.g., Crohn’s Disease Activity Index score < 150 points or a Harvey-Bradshaw Index score < 3). 5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine; AZA: Azathioprine; CI: Confidence interval; IFX: Infliximab; MTX: Methotrexate; n: Number of patients; RR: Risk ratio.